Recently, a bribery case involving a distributor of Changshan Pharmaceutical has drawn widespread attention. According to media reports, certain regional distributors of the company are accused of offering kickbacks, gifts, or other incentives to doctors to prescribe the company’s drugs preferentially, thereby boosting sales. Such practices not only violate China’s Anti-Unfair Competition Law and pharmaceutical industry regulations but also severely undermine public trust in the healthcare system and harm patient interests.Following the exposure of the incident, Changshan Pharmaceutical promptly responded, stating that the implicated distributor was an independent third-party partner. The company has terminated its cooperation with the distributor and is cooperating with relevant authorities in their investigation. It emphasized its robust internal compliance system, its zero-tolerance stance toward commercial bribery, and its commitment to strengthening oversight of its distributor network.This case once again highlights the gray areas persisting in pharmaceutical distribution channels. Despite intensified government efforts in recent years to crack down on commercial bribery in drug procurement and sales, some companies still attempt to circumvent regulations through covert means. Experts urge further refinement of policies such as the ‘two-invoice system’ and volume-based procurement, greater industry transparency, and enhanced end-to-end supervision of both pharmaceutical companies and their distributors to root out unethical marketing practices.
近日，常山药业（Changshan Pharmaceutical）的一起经销商涉嫌向医生行贿的案件引发广泛关注。据媒体报道，该公司部分区域经销商被指控通过给予回扣、礼品或其他利益，诱导医生优先开具其生产的药品处方，从而提升销量。此类行为不仅违反了《反不正当竞争法》和医药行业相关监管规定，也严重损害了医疗行业的公信力和患者权益。常山药业在事件曝光后迅速回应，表示涉事经销商为独立第三方合作方，公司已终止与其合作关系，并配合有关部门调查。同时，公司强调内部合规体系健全，坚决反对任何形式的商业贿赂，并承诺加强经销商管理与监督机制。此事件再次凸显医药流通环节中存在的灰色地带。尽管国家近年来持续加大对医药购销领域商业贿赂的整治力度，但部分企业仍试图通过隐蔽手段规避监管。专家呼吁，应进一步完善“两票制”、带量采购等政策执行，推动行业透明化，并强化对药企及经销商的全链条监管，从源头遏制不正当营销行为。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/13327.html